PHAT
Phathom Pharmaceuticals, Inc.
Healthcare — Biotechnology
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Price History
Fundamentals
| Market Cap | $840.23M |
| P/E Ratio (TTM) | - |
| Forward P/E | 7.32 |
| EPS (TTM) | $-2.09 |
| Dividend Yield | - |
| Profit Margin | -76.77% |
| Revenue Growth | 104.40% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $23.70 |
| Analysts | 10 |
| Next Earnings | Jul 30, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 59.9 |
| Beta | 0.51 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.31 |
| 52-Week Low | $7.61 |
| 50-Day Avg | $11.16 |
| 200-Day Avg | $12.70 |
| Avg Volume | $1.22M |
| Volume | $1.03M |
Performance Analysis
BULLISHPHAT shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report